19 results
10-Q
2018 Q3
ETON
Eton Pharmaceuticals Inc
20 Dec 18
Quarterly report
7:32am
develop;
injury to our reputation;
withdrawal of clinical trial participants;
costs to defend the related litigation;
a diversion of management’s time … and damage our brand and reputation.
Our product candidates may become subject to competition from counterfeit pharmaceutical products, which
10-K
2018 FY
ETON
Eton Pharmaceuticals Inc
25 Mar 19
Annual report
9:31am
may result in:
decreased demand for any of our product candidates or any future products that we may develop;
injury to our reputation;
withdrawal … product candidates, may have adverse effects on our revenues, business and results of operations and damage our brand and reputation.
Our product
DRS/A
x96zqk1u
28 Jun 18
Draft registration statement (amended)
12:00am
DEF 14A
0ho n42gkh8d2l50t
26 Apr 19
Definitive proxy
4:34pm
S-1
sra5xe0 6ui0
10 Aug 18
IPO registration
3:20pm
424B4
40h7l
13 Nov 18
Prospectus supplement with pricing info
5:10pm
S-1/A
tk053kjpp 5v63
25 Sep 18
IPO registration (amended)
12:00am
- Prev
- 1
- Next